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Contribution of Organ Transplantation 
to the Biology of Cancer 
Thomas E. StaTzi 
T he interface between transplantation and oncology has been an in· 
completely explored one with potential implications ranging from the 
simple and obvious to the most sophisticated and surprising. 
IMMUNOSUPPRESSION 
To succeed with transplantation, it is necessary to drastically alter 
the immune system of the recipient and to reduce thereby one of the 
natural defenses against malignant tumors. The principal advances in 
clinical immunosuppression I-I are summarized in Table 1. With each of 
the relatively small number of regimens, the effectiveness and practicality 
of therapy have been improved. The introduction of cyclosporine! and 
its combination with steroids' about a decade ago were a major event 
that made practical on a large scale the transplantation of extrarenal 
organs. 
Recently, we have developed and started clinical trials with an even 
more powerful and considerably less toxic agent called FK 506.' FK 506, 
like cyc1osporine, has a relatively specific effect on T -lymphocytes. Both 
cyclosporine and FK 506 inhibit the synthesis and expression of the 
cytokine, interleukin 2.'·10 
The combination of any of the immunosuppressive agents with con-
tinuously present antigens can induce "graft acceptance"" for reasons 
not adequately explained. In rodents, this is very easy to accomplish 
with FK 506, 'l the drug which seems destined to dominate all devel· 
opments in transplantation in the immediate future. 
IMMUNOSUPPRESSION AND THE TUMOR ENVIRONMENT 
More than two decades ago. we speculated 13 that the development 
of cancer, or accelerallon of its growth mIght be consequences of im· 
munosuppression. There were two principal lines of evidence for this 
hypothesis. 
Tht Accidtntal Transplantation of Malignant Tumors 
Becaust tumors follow the same rules of histocompatibility that de-
termine rejection. malignant tissues which are transplanted from one 
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TABLE 1. Immunosuppressive Drug Regimens Used Clinically 
(or Whole Organ Transplantation 
Year 
describt'd 
and 
Rt'ft'rt'nct' Agents reportt'd Place Deficiencies 
1 Aulhioprine 1962 BasIon Ineffective. dangerous 
2 Au thioprine-slerolds 1963 Denver Suboptimal 
3 ALG as adjunct 1966 Denver Suboplimal 
, Cyclophosphamide 1970 Dt'nver No advanuge net'pt (or 
substilult' for patients with 
azathioprine uathioprine toxicity 
5 Cyclosporine 1978-1979 Cambridge Suboptimal 
6 Cyclosporine-steroids 1980 Denvt'f Nephrotoxicity limits 
with or without dale: rt'jrction not 
other adjuncts' always controlled 
7 MonocionalOKTJ 1981 Boston High incidence of 
infection 
8 FD 506 1989 Pittsburgh Being evaluated 
'lymphoid depletion with Ihoracic duel drainage. anti· lymphocyte globulin (ALG}. OKT3. 
and/or azathioprine . 
human to another normally are rejected. About 25 years ago. several 
patients were given grossly normal kidneys from donors who had died 
of carcinomas of the lung. hypopharynx. thyroid. breast. or liver (sum· 
marized in Ref. 14). Micrometastases were present in these seemingly 
normal cadaveric organs because the immunosuppressed recipients of 
the kidneys developed metastases from the donor tumors. In two of the 
patients. the tumors had become autonomous by the time the diagnOSis 
was made. Although immunosuppression was stopped. these patients 
died of widespread metastases. 15.16 However, in two other cases, 17, 18 
carcinomas which had diffusely infiltrated the renal graft and surround-
ing area or even had spread to both lungs disappeared without a trace 
after azathioprine and prednisone were stopped; at the same time the 
kidney grafts were rejected. 
Even in recent times, tumors have been accidentally transplanted. 19 
In April 1986. a liver. heart, and two kidneys were procured from a 36-
year-old female donor who had died from a stroke. Later. stored donor 
serum was shown to have an astronomical level of chorionic gonado· 
trophin. Metastatic choriocarcinoma developed in the liver recipient 
and in both kidney recipients. The heart recipient was spared. at least 
for the first half year. Tumor was irradicated in one of the kidney re-
cipients after graft nephrectomy and methotrexate therapy. The other 
two recipients died within a few months of widespread metastases. 
All IncTtllsed Incidence of De Novo Tumors 
A more subtle demonstration of the liability of depressed immu-
nologic surveillance is the high incidence of de novo tumors in patients 
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under chronic immunosuppression. Earlier observations by Dr. Robert 
Good and his associates 2D had already identified this risk in patients 
with natural immune deficiency states. We reported the same ominous 
development in our immunosuppressed kidney recipients at several 
meetings in 1968 (summarized in Ref. 14). The unusually high incidence 
was emphasized of the lymphoreticular tumors (then called recticulum 
cell sarcomas or histiocytic lymphomas), which are now known to be 
B-celllymphomas. 21.22 There was an increase also of epithelial and other 
malignancies. Dr. Israel Penn, who joined our faculty at the University 
of Colorado in July, 1968, made these cases23 the nucleus of an inter-
national registry of de novo malignancies in transplant recipients24 which 
he still maintains. Two decades later, more than 5000 cases have been 
contributed. 25 The overall profile of the original cameo reports has not 
been changed in principle by the accrual of these huge numbers. 
An infectious etiology. Because of a high incidence in organ recipients 
of the facial and uterine cervical cancers that are associated with in-
fections of the Herpes virus family, we suspected at the outset that de 
novo tumors under immunosuppression might have an infectious etiol-
ogy.24 The B-cell lymphomas which have been linked to Epstein-Barr 
virus provide the best example. The characteristics of such tumors were 
described by Klein and Portillo in patients with a familial immune de-
ficiency disease.26 and convincing evidence that they were caused by 
primary infection or reinfection with Epstein-Barr virus under immu-
nosuppression has been provided from many transplant centers, begin-
ning with the insightful reports of Simmons and his associatesY A virus 
etiology is suspected but not established for other de novo tumors under 
immunosuppression. 
Tumor regression with immune modulation. A special and reasonablv 
predictable feature of the Epstein-Barr associated B-celllymphomas i's 
their regression in the majority of cases when immunosuppression is 
lightened or stopped. 22 We recognized long ago the responsiveness of 
histiocytic lymphomas to immune modulation,I4.28.29 but uncertainty 
about the nature and histopathologic classification of these lesions made 
interpretation of the dramatic clinical events following discontinuance 
of immunosuppressIOn difficult. The instinctive conclusion of skeptics 
was that the regression of a mass after stopping or reducing immuno-
suppression implied that the diagnosis of lymphoma must have been 
incorrect in the first place. The term '"pseudolymphoma'" was applied. 2I 
However. with modern methods of lymphoma classification,3D including 
those made possible with gene probe techniques. 3I the conclusion became 
inescapable that the complete involution of true B-cell neoplasms. in-
cluding many with monoclonal constituency could be accomplished by 
allowing the recipient's immune system to recover. This was the first 
clear example in humans of immune surveillance. The prospects of re-
covery from these virus-associated malignancies can be improved further 
by treatment with the anti-viral agent. acyclovir.J2 
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We have also seen growth or recession of Kaposi's sarcomas, cor-
responding perfectly with the institution of discontinuance of cyclo-
sporine-steroid therapy. 3J It is almost certain that the complete disap-
pearance of a malignant dysgerminoma in a kidney transplant reCipient 
was because of restored immune surveillance after discontinuance of 
immunosuppression. 34 Ironically, the case had been reported originally 
as a claim that chemotherapy and irradiation were effective in spite of 
immunosuppression. 35 
Aids plus immunosuppression. During the first half of the 19805. when 
screening (or HIV was not available. an accidental experiment was begun 
which continues to the present. Twenty-five patients were treated with 
liver. heart. or kidney transplantation without knowing that they already 
were HIV carriers, or would be infected perioperatively with transfusions 
or with the donor organs. 36 Twelve of these patients are still alive 11/" 
to 7 years later. none with tumor. However. one liver reCipient died of 
an intra-abdominal immunoblastic sarcoma 19 months postoperatively . 
Another (whose original disease was sclerosing cholangitis) developed 
a carcinoma o( the rectum which was resected 2 years ago with no sub-
sequent recurrence. These patients with their natural immune deficiency 
plus immunosuppression have had organ rejection as vigorous as normal 
patients. They have not had the overwhelming incidence of de novo 
tumors that might have been predicted. 
SURVEILLANCE REVISITED VIA LIVER REGENERATION 
The concept of immunotherapy is based upon two inherent premises 
in the surveillance hypothesis. The first is that the tumor cell is sufficiently 
different from normal cells. perhaps by virtue of tumor specific antigens, 
to be recognized as alien. The second premise is that a malignant tumor 
cell will be a more sensitive prey to immunologic attack than the healthy 
cell. The simplistic hypothesis of immune surveillance 37 along With its 
therapeutic implications was the subject of a complete Issue In 1971 
(Vol. 7, p. 3-178) of a journal then called TransplantatIon Revuu's and 
later renamed ImmunologIcal Reviews. In a subsequent Issue only 5 years 
later (1976; 28:3-98) were described inconSistenCies of the surveillance 
hypothesis,3S failure of the hypothesis to explain why tumors never 
developed in the T-cell deficient nude mice,)9 and reasons why it should 
be abandoned. Discussion of the reverse stampede away from the sur-
veillance hypothesis is beyond the scope of my assignment today. How-
ever, I have brought up the subject in order to ask if some recent work 
on liver regeneration might permit a new and different look at immune 
surveillance. Liver regeneration is an example of intense cell renewal 
rivaling or surpassing that seen in the most rapidly growing malignant 
tumors. Yet. the process is under perfect biologic control and entirely 
self-limiting. Why? 
J. 
- . __ .. ---------------
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We have studied liver regeneration in rats submitted to 40 and 70 
per cent partial hepatic resection, with or without immunosuppression 
with the two most potent immunosuppressive drugs available, namely 
cyclosporine40. 41 and the even more powerful new agent named FK 506. 41 
Both drugs augment regeneration. 40•41 The mechanism of this effect is 
obscure. Although the two drugs have completely different molecular 
structure, they have in common the specific depression of the T-cell 
response. 9 •IO We have asked if a natural function of the immune system, 
and particularly its T-cell component might be to "brake" (modulate) 
hepatocyte replication, but only when this replication is occurring at 
an increased rate. Thus, cyclosporine and FK 506 markedly augment 
mitoses if it is already higher than normal in regenerating livers, in 
livers damaged by Eck fistulas and in livers stimulated with thyroxin. 42 .43 
This is a phenomenon of the intact animal. Neither drug has any effect 
on resting or stimulated (with epidermal growth factor) hepatocytes in 
culture. The mitotic rate is not increased, meaning that the stimulation 
of cell renewal is not a direct effect on the liver cells. 42 
In any discussion of regeneration, a central question is why the 
regenerating liver knows how to stop its regrowth at the proper size 
and time. Endogeneously produced chemical inhibitory factors or hor-
mones often are candidate control substances. 44 .45 Perhaps, insufficient 
attention has been paid to immune modulation as the explanation. Re-
search on immunosuppression for transplantation, combined with in-
vestigations of hepatic regeneration, could lead to a better understanding 
of the relation between growth control and immune function. There 
could be major implications in oncology and revision of the meaning of 
surveillance. 
TRANSPLANTATION TO INCREASE SURGICAL MARGINS 
Total HepattCtomy and Liver Transplantation 
In the early trials of orthotopic liver transplantation, the ideal in-
dication for liver replacement was thought to be a malignant tumor 
which could be removed completely by total hepatectomy, but not by 
con ventional subtotal hepa tic resection. U nfortuna tel y, the ma'jority of 
recipients who survived liver transplantation died later of metastatic 
disease. 13.".47 Nevertheless, some patients did live for a long time, and. 
in fact. practically all of those reCipients who had small incidental ma-
lignancies in livers removed for other reasons (t.g., biliary atresia) were 
rendered tumor free.46 The longest survivor after liver transplantation 
in the world (now 20 years) had a 2-cm hepatoma in her cirrhotic liver, 
and 4 mg% of a-fetoprotein in her preoperative serum. Thus, the size 
and stage of development of the malignancy was important in the tumor 
prognOSis. 
The high incidence of tumor recurrence after liver transplantation 
has prompted speculation, 13.14 that immunosuppression itself might fa-
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vor the growth of micrometastases which are outside of the liver or 
expelled from it during the transplantation. This might be a special 
problem with bulky tumors. In addition to size. the histopathology of 
the tumor also influenced prognosis. Patients with the so-called fibro-
lamellar variant of hepatocellular carcinoma have done well after liver 
transplantation. even when the lesions were enormous. U In contrast, 
patients with large conventional hepatocellular carcinomas almost al-
ways have developed recurrence. 46 In spite of initially optimistic ex-
pectations. very small duct cell carcinomas in the hilum of the liver 
(I<latskin tumors) have had a dismal prognosis (reViewed in Ref. 47). In 
between these extremes are other tumor types such as hemangioen-
dothelial sarcomas. 49 Even patients with massive liver metastases have 
had an overall 2 year survival of 50 per cent. the best results being with 
neuroendocrine tumors (in particular, carcinoids) and sarcomas. 50 
Thus, the concept of using liver transplantation to extend resectabil-
ity limits has not been completely abandoned. In the major liver trans-
plantation centers around the world. the incidence of recipients with 
hepatic tumors ranges from 4 to 40 per cent. f7 the low figure being ours. 
Tumor recurrence in all reported series is responsible for a steady decline 
in survival beginning at 4 to 6 months. 47 Adjuvant chemotherapy, usually 
including adriamycin, is being used increasingly in addition to liver 
replacement. but there is no proof as yet that the outcome will be fa-
vorably influenced thereby. 
UPPER ABDOMINAL bub~K;rboAqflk 
It is possible that even the total hepatectomy made possible by 
transplantation is a fundamentally inadequate resection. Beyond the 
context of transplantation, an understanding of the embryonal origin 
of the liver, pancreas, and duodenum can help in understanding why 
tumor operations on these organs are so ineffectual. In the development 
of the fetus, the liver and pancreas begin as ventral and dorsal diverticula 
from that portion of the foregut that later becomes the duodenum (Fig. 
lA). The anatomic relationships of these organs becomes more complex 
during their differentiation and rotation, but their intimacy including 
the sharing of the terminal hepatic and pancreatic duct drainage into 
the duodenum is not lost (Fig. 18). Thus, it is not surprising that ma-
lignant tumors developing at or near the original duodenal outpouchings 
are notoriously refractory to treatment by resection even if these are 
localized to a portion of a single organ. Tumors that originate in one of 
the three organs (liver, pancreas, or duodenum) and metastasize to the 
others or to the transverse mesocolon or colon have been considered to 
be categorically non-resectable. 
During the last 1\/2 years, we have examined the premise that radical 
excision of most of the foregut could allow complete removal of certain 
hepatic duct cell, duodenal. gastric. and pancreatic malignancies that 
: I 
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Flcs. 1 A and 18. Delinulion in embryonillife of that region of the gastrointestinal tract 
(dirk shaded) that was resected in the organ cluster operation (AI. E. esophagus; LB. lung 
bud; L. liver: p, pancreas. The adult organs deriving from the shaded primitive analage (S) 
(By permission of Starzl TE. Ann Surg 1989: 210:374-386.) 
had already spread to the liver as well as extirpation of primary liver 
tumors whose spread was downward. Thirty-three patients with these 
seemingly untreatable malignancies underwent removal of the liver. 
stomach. spleen. duodenum. proximal jejunum. terminal ileum. and as-
cending and transverse colon (Fig. 1 B). 
Replacement with organ clusters. In the first IS patients. 5 1.52 the void 
in the upper abdomen was filled with cadaveric organ cluster grafts that 
included the liver. pancreas. duodenum. and variable amounts of prox-
imal jejunum (Fig. 2). The primary tumors were duct cell carcinomas (n 
= 7). carcinoids (n = 3). cholangiocarcinomas (n = 2). sarcomas (n = 2). 
and one hepatoma. Their locations are summarized in Table 2. The leSIons 
usually involved multiple organs (Table 2) and were untreatable by anv 
conventiona I criteria. The opera tions were performed between July 1988 
and March 1989, and for the survivors there are potential follow-ups 
of 7 1h months to almost II/: years (Table 3). Four of the IS recipients 
died within the first 4 months. all of technical or mechanical compli-
cations. Of the 11 who survived for definitive observation. 2 developed 
recurrences which caused death. and a third one who is clinically well 
has had stable nodules in the lungs for a number of months. Four patients 
with sarcomas and carcinoid tumors have had no recurrences (Table 3). 
Other survivors had duct cell cancers (n = 3). a cholangiocarcinoma (/I 
= 1). and a hepatoma (n = 1). Duct cell cancers have given the worst 
results (Table 4) with the prognosis directly linked to the presence or 
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Flc. 2. Completed supenor mesenlerlc vein reconSlructlon and usuli glslrOlnltstlnal 
ffconstrucllon. (By permISSIon of Surzl TE. Ann Surg 1989; 210:374-386 I 
absence of lymph node metastases. The experience so far supports further 
cautious trials with this drastic cancer operation. 
With transplantation of tht livtT alonl!. It is not clear whether the 
complete cluster replacement graft is necessary. We have performed the 
upper abdominal exenteration with transplantation of the liver only.53 
The penalty for the limited organ replacement is diabetes mellitus and 
exocnne pancreatic insufficiency. Eighteen such operations have been 
carried out, but with (ollow-ups that are too short to permit definitive 
.. 
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T AILE 2. Primuy Tumor Location in Organ Cluster SerifS· 
Bile ducts 
Liver 
Pancreas 
Stomuh 
Duodenum 
7 
3 
I 
I 
3 
• Number of organs involved: four, 2; three, 4; two, 5; and one, 4. 
conclusions. Although the simpler procedure imposes diabetes mellitus 
and exocrine pancreatic insufficiency, it eliminates the technical com-
plications associated with whole pancreas grafts. One potential strategy 
for the future is to perform this modified operation, but to then carry 
out free transplantation into the portal vein of the islets prepared from 
the pancreas of the liver donor. Islet ceIl transplantation has never been 
successfully done in humans, but the remarkable potency of FK 506 8 
mentioned. earlier is an incentive for such a trial which is planned for 
later this year. 
SUMMARY 
Patients under immunosuppression variably have lost their immune 
tumor surveillance. This has been demonstrated by accidentally trans-
planting malignant tumors to these patients, and by an increased risk 
of de novo tumors of which some have a viral etiology (Epstein-Barr 
virus) and well-mapped oncogenes. When immunosuppression is light-
ened or stopped in patients with B-celllymphomas, with Kaposi's sar-
comas and possibly other tumor types, the neoplasms f!1ay go away. The 
immune system may be involved as well in growth control of normal 
cells. FK 506 and cyclosporine, two drugs which are T-cell specific im-
munosuppressants, greatly augment the liver regeneration that follows 
T AILE 3. Survival by DiagnOSIs: 15 Cluster ReCIpients· 
PI Time an monlhs 
Duct cell CA 3/1 8. II. 12 
Sarcoma 2/2 14. 16 
Carcinoid 2/3 8. 13 
Cholangio CA 1/2 9 
Hepatoma 1/1 9 
• Dales: July 22. 1988 10 Much 24. 1989; ages: 27-49 years; Ind sn: 9 males. 6 fematl's. 
TABLE 4. Duct CI'II Clncl'r (n - 7) 
Survival (8-12 months) 
Negalavl' nodI'S 
PositivI' nodI'S 
3/1 
3/4 
0/3 
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partial hepatectomy and they modulate liver growth in other situations 
including Eck fistula. 
In spite of the handicaps of immunosuppression. liver transplan-
tation has been used to treat patients with primary liver tumors and 
even metastatic hepatic malignancies. A newer procedure of upper ab-
dominal exenteration has been used recently to remove upper abdominal 
malignancies which were previously beyond surgical therapy because 
of their involvement of multiple organs including the liver, pancreas, 
duodenum. or other structures. Although recurrences have been common, 
many patients have been rendered tumor free by these seemingly radical 
operations which are apt to playa slowly increasing role in the thera-
peutic armamentarium of the future. 
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Discussion 
Margaret L. Kripke: Dr. Starz!. in the regeneration of normal liver. as far 
as I am aware, there is no known difference in the regeneration of normal liver 
in. say. nude mice than in normal mice. So. if this were really a T-cell immunological 
phenomena. you would expect to see differences in regeneration of those cases. 
Would you comment? 
Thomu E. Stud: This is an important point. There are reports of normal 
hepatic regeneration in nude mice. You can rest assured that we have our own 
colony of nude mice and are doing our own experiments to confirm or deny these 
reports. There are other studies that can and are being done. including regeneration 
studies with monoclonal anti-CD. antibody treatment. Also. in a larger animal 
model. the dog. we have a proficient way of depleting T -cells with thoracic duct 
fistula. after which we can study regeneration with a split liver model that has 
been used to assess other growth control factors such as insulin and a hepatic 
stimulatory substance that can be found in regenerating livers. 
David Skinner: On that same line. your data show that the brake on re-
generation is the total mass. It stops as the mass gets larger. 
Starzl: It stops. but those experiments were done for somewhat different 
reasons. The treatment schedule was to pretreat for 3 days and to give the final 
dose of immunosuppression on the day of liver resection. Thus. active drug therapy 
had been stopped at the time regeneration was occurring and receded. When we 
first discovered this augmentation of regeneration WIth cyclosponne in 1985 and 
1986. the experiments were done with the hypotheSIS that regeneration would 
be reduced. We were concerned about whether transplanted livers under im-
munosuppression would be able to accommodate themselves to the appropnate 
size. and also we feared that if we had to gIve Adnamvcin to liver recipIents 
being treated for cancer. there would be a double indemnltV If both agents (cy-
c1osporine and adnamycin) retarded regeneration (as adnamyclO was known to 
do). What will happen to regeneration with continuous therapy or whether the 
liver mass will be changed with chronic therapy will have to be learned with 
further experimentation. We are looking into the matter with the canine split 
liver model which I mentioned a moment ago. After Eck fistula (portacaval shunt). 
the liver quickly atrophies and has disruption of its hepatocyte ultrastructure. 
Both cyclosporine and FK 506 prevent this and stimulate reparative changes. not 
limited to increased replication. They also preserve the integrity of the organelles 
in the same way as insulin does. Since both cyclosporine and FK 506 are given 
orally and reach the liver in high first-pass concentration. we believe that these 
agents might be capable of promoting healing in the event of liver injury. and 
with a variety of acute or chronic liver diseases. There could be many therapeutic 
implications having nothing to do with oncology. 
Sir James Gowans: In the animals given cyclosponn. where you observed 
the recent regeneration of the liver. did you look up the cell turnover and other 
tissues like the gut and the skin. bone marrow. for example. to see how those 
adjust? 
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In addition. you hinted you might get an added bonus under cyclosporine 
and the healing itself might be elsewhere. 
Stuzl: Well. we do not have the complete answer to that. Jim. but we have 
done experiments with 50 per cent small bowel resection. and unilateral ne-
phrectomy. The regeneration of the residual bowel and contralateral kidney (re-
spectively) was not increased more than in the controls. So for the moment. we 
are stuck with the idea that this effect is liver specific. 
John D. Minna: That is not hypertrophy. That is not cell division? 
Stud: These were DNA synthesis end points, 
Minna: On the marrow? 
Stuzl: We did nothing other than those two organs (bowel and kidney). 
Minna: How about healing? 
Stud: Well. we do not have any precise measurements. but wound healing 
under cyclosporine and FK 506 is grossly normal. 
Minna: It is not always perfect. 
Joseph Fortner: What is the effect on regeneration of the cirrhotic liver? 
Stud: We do not have an answer for that question. but what we do have. 
loe. is the observation that we just published in Lancet about the effect of FK 
506 on chronically rejecting Ih·ers. These livers look cirrhotic in that there is 
lobular collapse and fibrosis, The pathology is so advanced that we never have 
been able to alter the course, What has happened with FK 506 therapy is that 
the autoimmunity (here being rejection) has been stopped. followed by healing 
and repair beyond what you would expect just by discontinuing the insult. That 
is one of the reasons why we are so fascinated by the so-called hepatotrophic 
effect that can be so precisely studied in the dog and rat. These drugs might. as 
you are implying. find application in the treatment of chronic liver diseases. not 
even necessa~ily with an autoimmune etiology. If they had a reparative effect on 
the cirrhotic liver. for example caused by alcoholism. It could become a therapeutic 
Issue, That is. in essence. where we are aiming, 
